Design, Synthesis, In Vitro and In Vivo Evaluation of Novel Anti-Alzheimer’s (1E,4E)-1,5-Bis[(het)aryl]penta-1,4-dien-3-one Derivatives
Géssica Oliveira Mendes, Lucas Diego Pereira Bento, Thiago Malverde de Oliveira, Deyse Brito Barbosa, Guilherme Saraiva Tsui, Ellen Nunes Gomes, Raphaela Oliveira Sales, Mateus Silva de Castro Rocha, Michel Pires da Silva, Tiago Alves de Oliveira, Eduardo Habib Bechelane Maia, Daniel Luciano Falkoski, Isabella Flores de Souza Marra, Lorena Silva Matos Andrade, Liliane Costa Vanessa Pereira Mendes, Bianca de Souza Fonseca, Lucas Matheus Gonçalves de Oliveira, Victor Diogenes Amaral da Silva, Paulo Batista de Carvalho, Alisson Marques da Silva, Alex Gutterres Taranto, Laila Cristina Moreira Damázio, Marcelo Siqueira Valle, Franco Henrique Andrade LeiteBackground/Objectives: Alzheimer’s disease (AD) is a progressive, multifactorial neurodegenerative condition characterized by neurofibrillary tangles, neuronal loss, cognitive impairment, and accumulation of β-amyloid plaques. Considering the limitations of current treatments, which present adverse effects and only alleviate symptoms without modifying disease progression, there is an urgent need for new therapeutic approaches. This study aimed to investigate the neuroprotective potential of synthetic derivatives of (1E,4E)-1,5-bis[(het)aryl]penta-1,4-dien-3-ones, focusing on the inhibition of the cholinesterase enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), targets directly related to the cholinergic deficit observed in AD. Methods: The compounds were initially synthesized by aldol condensation reactions, with subsequent physicochemical characterization. They were then subjected to in silico assays that demonstrated high binding affinity to the active sites of AChE and BChE. The derivatives were evaluated in vitro for their inhibitory activity on these enzymes and in vivo in an experimental model of AD induced by streptozotocin in Wistar rats. Results: The synthesized derivatives showed favorable predicted interactions with the active sites of AChE and BChE, supporting their potential as cholinesterase inhibitors. In vitro assays demonstrated inhibitory activity against both enzymes, with selected derivatives showing improved activity compared with the parent scaffold. In the in vivo model, treatment with the selected compounds was associated with neuroprotective effects, suggesting preservation of nervous tissue integrity under AD-like conditions. Conclusions: These findings indicate that derivatives may represent promising candidates for further investigation as multitarget agents for AD. The study reinforces the relevance of integrating organic synthesis, molecular modeling, enzymatic assays, and in vivo evaluation in the search for new therapeutic strategies for neurodegenerative diseases.